Search

everythinglearnresearchcommunity

for

Search:↓

User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.

User shared progress after 5 months of using finasteride, minoxidil foam, and weekly derma rolling. Positive feedback highlights increased hair count and thickness.

The conversation is about finding a foam product that combines minoxidil and tretinoin for hair loss treatment. The user is seeking purchasing options for this specific combination.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.

Hair loss treatments like dutasteride, finasteride, minoxidil, and RU58841 are discussed, with mixed results and ongoing hope for better solutions. Users express skepticism about a cure, sharing experiences with various treatments and lifestyle changes.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The user has been using a combination of oral and topical minoxidil, topical finasteride, RU58841, Nizoral, and microneedling for hair loss treatment. They report improvement in hair thickness except for the crown area, which has not changed.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.

The conclusion of the conversation is that the user experienced noticeable regrowth of hair after using dutasteride as a single treatment for about 1.5 years. No before photos were available.

A user is considering switching from oral minoxidil to a combination of 5% topical minoxidil and tretinoin to reduce hypertrichosis. They hope this combination will be effective without causing excessive body hair growth.

The post discusses using RU58841 and 5% minoxidil for hair loss treatment, with RU applied to the temples and crown, and minoxidil used twice daily. Users debate the effectiveness of RU58841 compared to minoxidil alone.

The user experienced significant hair regrowth on temples and beard using a combination of Dutasteride, Tretinoin, and topical Minoxidil, but stopped oral Minoxidil due to heart pain. The user switched from Finasteride to Dutasteride due to aggressive hair loss.

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

The user is considering a hair transplant after 4 years of using finasteride, minoxidil, microneedling, and scalp massages for hair regrowth. Opinions differ, with some suggesting continuing current treatments and others recommending a transplant to reduce maintenance.

The conversation is about using topical tazarotene with minoxidil for hair loss treatment. A user suggests using a lower strength than 0.025% for daily application.

The user is considering adding tretinoin cream to their hair treatment routine, which currently includes minoxidil and finasteride, to enhance results. They seek advice on its effectiveness, usage frequency, side effects, and whether it complements microneedling.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

User asks about Pyrilutamide release in Europe, specifically Germany, and considers importing it from China. No specific treatments mentioned.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

Hair regrowth treatments, including stem cell injections, are discussed, with skepticism about their effectiveness compared to Minoxidil and finasteride. Derma stamping is mentioned as effective when used with Minoxidil, finasteride, and dutasteride.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.